Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection

Journal of Managed Care Pharmacy

Volumn 13, Issue 9, 2007, Pages 790-798

  Tencer, Thomas ^a   Friedman, Howard S ^b   Li McLeod, Josephine ^c   Johnson, Kathleen ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Analytic Solutions LLC   (United States)

^c BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALPHANINE SD; AUTOPLEX T; BEBULIN VH; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; HELIXATE FS; HEMOFIL M HUMAN; HUMATE P HUMAN; HYATE C ANTIHEMOPHILIC FACTOR; KOATE DVI; MONARC M; PROFILNINE SD; PROPLEX T FACTOR IX COMP; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG COST; FOLLOW UP; GASTROENTEROLOGY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEMOPHILIA; HEPATITIS C; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OUTCOMES RESEARCH; OUTPATIENT CARE; RETROSPECTIVE STUDY; UNITED STATES;

EID: 38149091426     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.9.790     Document Type: Article

References (41)

1. Leveton LB, Sox HC Jr., Stoto MA, eds. HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. Washington, DC: National Academy Press; 1995.
2. Brettler DB, Alter HJ, Dienstag JL, et al. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood. 1990;76:254-56.
3. Kroner BL, Rosenberg PS, Aledort LM, et al. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1994;7:279-86.
4. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program. 2004:1-33.
5. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. 1997;350:1425-31.
6. Gonzalez SA, Talal AH. Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications. Semin Liver Dis. 2003;23:149-66.
7. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis. 2001;183:1112-15.
8. Telfer P, Sabin C, Devereux H, et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol. 1994; 87:555-61.
9. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med. 1999;107:79S-84S.
10. Maier I, Wu GY. Hepatitis C and HIV co-infection: a review. World J Gastroenterol. 2002;8:577-79.
11. Sabin CA, Telfer P, Phillips AN, et al. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infec Dis. 1997;175:164-68.
12. Nunez M, Soriano V. Current concepts in the management and treatment of hepatitis C in HIV-infected patients. Ann Hepatol. 2005;4:151-60.
13. Kontorinis N, Agarwal K, Dieterich DT. Treatment of hepatitis C virus in HIV patients: a review. AIDS. 2005;19:S166-73.
14. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-97.
15. Globe DR, Cunningham WE, Andersen R, et al. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A. Haemophilia. 2003;9:325-31.
16. Miners AH, Sabin CA, Tolley KH, et al. Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? J Intern Med. 2000;247:493-99.
17. Kennelly JM, Tolley KH, Ghani AC, et al. Hospital costs of treating haemophilic patients infected with HIV. AIDS. 1995;9:787-93.
18. Globe DR, Curtis RG, Koerper MA, et al. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia. 2004; 10(suppl 1):63-70.
19. Bohn RL, Avorn J, Glynn RJ, et al. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost. 1998;79:932-37.
20. Kern M, Blanchette V, Stain AM et al. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr. 2004;145:628-34.
21. Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood. 2003;102:2358-63.
22. Molho P, Rolland N, Lebrun T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. Haemophilia. 2000;6:23-32.
23. Stanley S. The need for continuing vigilance: addressing the threat for transmission of blood-borne infectious diseases. Semin Hematol. 2006;43(suppl 3):S17-S22.
24. Heemstra HE, Zwaan T, Hemels M, et al. Cost of severe haemophilia in Toronto. Haemophilia. 2005;11:254-60.
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-19.
26. Stanworth SJ, Bolton MJ, Hay CR et al. Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Haemophilia. 1998;4:109-14.
27. Helal A. HIV protease inhibitors and increased bleeding in hemophilia? CMAJ. 1997;156:90.
28. Wilde JT, Lee CA, Collins P, et al. Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. Br J Haematol. 1999;107:556-59.
29. Racoosin JA, Kessler CM. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia. 1999;5:266-69.
30. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996;335:1081-90.
31. DELTA Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee [erratum appears in Lancet, September 21, 1996;348(9030):834]. Lancet. 1996;348:283-91.
32. Mole L, Ockrim K, Holodniy M. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Pharmacoeconomics. 1999;16:307-15.
33. Purdum AG, Johnson KA, Globe DR. Comparing total health care costs and treatment patterns of HIV patients in a managed care setting. AIDS Care. 2004;16:767-80.
34. Djulbegovic B, Goldsmith G, Vaughn D. Comparison of the quality of life between HIV-positive haemophilia patients and HIV-negative haemophilia patients. Haemophilia. 1996;2:166-72.
35. Trippoli S, Vaiani M, Linari S, et al. Multivariate analysis of factors influencing quality of life and utility in patients with haemophilia. Haematologica. 2001;86:722-28.
36. Barr RD, Saleh M, Furlong W, et al. Health status and health-related quality of life associated with hemophilia. Am J Hematol. 2002;71:152-60.
37. Miners AH, Sabin CA, Tolley KH. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia. 1999:378-85.
38. Fischer K, van der Bom JG, van den Berg HM. Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia. 2003;9(suppl 1):75-81; discussion 2.
39. Szende A, Schramm W, Flood E, et al. Health-related quality of life assessment in adult haemophilia patients: a systematic review and evaluation of instruments. Haemophilia. 2003;9:678-87.
40. Bohn RL, Aledort LM, Putnam KG, et al. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia. 2004;10:63-68.
41. Chang H, Sher GD, Blanchette VS, et al. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada. Haemophilia. 1999;5:247-52.